Erratum to Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults

被引：0
|
作者：
M. Sanford
机构：
来源：
Drugs | 2012年 / 72卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2176 / 2176
相关论文
共 50 条
  • [21] Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
    McLaughlin, John M.
    Swerdlow, David L.
    Khan, Farid
    Will, Oliver
    Curry, Aaron
    Snow, Vincenza
    Isturiz, Raul E.
    Jodar, Luis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 841 - 849
  • [22] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Ordonez, Jaime E.
    Orozco, John J.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [23] Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13-Valent polysaccharide conjugate vaccine
    Alicino, C.
    Barberis, I.
    Orsi, A.
    Durando, P.
    MINERVA MEDICA, 2014, 105 (01) : 89 - 97
  • [24] An Open-label Trial to Assess the Safety of 13-Valent Pneumococcal Conjugate Vaccine in Older Adults, Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.
    Schwarz, T. F.
    Pauksens, K.
    Juergens, C.
    Jayawardene, D.
    Emini, E. A.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S30 - S30
  • [25] Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
    Gladstone, Rebecca A.
    Jefferies, Johanna M.
    Faust, Saul N.
    Clarke, Stuart C.
    EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 889 - 902
  • [26] Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
    Schmoele-Thoma, Beate
    van Cleeff, Martin
    Greenberg, Richard N.
    Gurtman, Alejandra
    Jones, Thomas R.
    Sundaraiyer, Vani
    Gruber, William C.
    Scott, Daniel A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 575 - 583
  • [27] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [28] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [29] Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine
    Bryant, Kristina A.
    Block, Stan L.
    Baker, Sherryl A.
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRICS, 2010, 125 (05) : 866 - 875
  • [30] Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
    Esposito, Susanna
    Principi, Nicola
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
12345